Wednesday, December 9, 2020

8:22 PM

Pulmonary Rehabilitation

Cochrane review -12 RCT

Increase 6MWT & QOL

Pulmonary rehab reduces ILD re admissions

In this large, diverse cohort of patients with fibrotic ILD, we demonstrate a significantly better survival in patients who had clinically important gains in 6MWD with PR, compared to those who did not. With data from prospective trials lacking, these findings may suggest a potential survival benefit from PR in patients with fibrotic ILD.

Ambulatory oxygen

AMBOX

Improvement of breathlessness score & chest symptoms

IPF

Prednisolone+ Azathioprine+ NAC

PANTHER IPF

More hospitalizations & mortality

Perfenidone

CAPACITY

ASCEND

Improves survival, slow FVC decline

RECAP

RECAP was an open-label extension study that assessed the long-term safety of Pirfenidone patients with IPF who completed one of the ASCEND or CAPACITY Phase 3 trials.